Allergic Rhinitis Probiotics Capsules

Product name: allergic rhinitis probiotics capsules
Product specifications: 30 capsules/box
Product weight: 0.5 g/tablet
Indications: The strain composition provided by this product can quickly relieve symptoms such as nasal itching, sneezing, runny nose, etc., and has a significant therapeutic effect on allergic rhinitis.
Instructions for taking: 0.5 g/tablet, 2 pills each time, once/d.
Preservation method: Store in a cool and dry place, preferably refrigerated at 4°C.
Viable bacteria count:  probiotic mixture (40 billion CFU/g), Bifidobacterium longum HH‑BL18 (10 billion CFU/g), Bifidobacterium lactis HH‑BA68 (10 billion CFU/g), Lactobacillus rhamnosus PB‑LR76 (10 billion CFU/g) and Lactobacillus reuteri PB‑LR09 (10 billion CFU/g).
Other ingredients: fructooligosaccharides, galactooligosaccharides.

2. Technical background
Allergic rhinitis (hypersensitive rhinitis), also known as allergic rhinitis (AR), refers to a condition in which a susceptible individual is exposed to an allergen, mainly mediated by immunoglobulin E (IgE), and the body's immune active cells. It is a chronic inflammatory disease of the nasal mucosa with the main symptoms of episodic sneezing, runny nose, and nasal congestion, involving cytokines and other factors.
Currently, loratadine is mainly used to treat allergic rhinitis to relieve related symptoms such as sneezing, runny nose, nasal itching, nasal congestion, eye itching, and burning sensation. However, its therapeutic effect and cure rate are not significant. Studies have shown that supplementing the normal flora of the respiratory tract appropriately can maintain the balance of the respiratory microecology, increase its antagonistic effect on foreign pathogenic bacteria, and inhibit their growth. At the same time, it can also provide signals that promote immune cell maturation and tissue endothelial differentiation, improving the body's immune system function.
Increasing the number of probiotics in the respiratory tract to prevent respiratory diseases and improve the prognosis of respiratory diseases is a method worthy of attention.

3. Mechanism of probiotics improving respiratory diseases
Research shows that upper respiratory tract probiotics can achieve anti-infection and improve immunity through multiple immune pathways: (1) Upper respiratory tract probiotics have a strong binding ability to upper respiratory tract mucosal epithelial cells and interfere with the interaction between pathogenic bacteria Streptococcus pyogenes and human epithelial cells Adhesion prevents pathogenic bacteria from invading the upper respiratory tract mucosa; (2) Upper respiratory tract probiotics produce sufficient antimicrobial peptides, which can kill pathogenic bacteria and reduce the use of antibiotics; (3) Upper respiratory tract probiotics can activate The immune system produces anti-infection immune substances, increases the concentration of antiviral and antibacterial substances in saliva, and reduces the body's abnormal inflammatory response, thereby enhancing the body's effective antiviral and antibacterial capabilities.

4. Hehe Biological Prevention and Treatment of Allergic Rhinitis Strains
Source of strain: Isolated from the adult intestine, the fermentation temperature is 36-38°C, the fermentation time is 6-36 hours, and the culture medium used is MRS culture medium or a modified culture medium containing MRS culture medium.
Strain identification: isolate and purify the strain, use the 16S rRNA gene as a Marker fragment, amplify the 16S rRNA sequence in the gene with universal primers, and then perform electrophoresis detection and compare it with the NT database to obtain species information with similar sequences. With the help of homologous The comparison method assisted in determining species information. The classification was named Bifidobacterium longum, and the strain number was HH‑BL18.

Strain preservation: Bifidobacterium longum HH‑BL18 (Bifidobacterium longum HH‑BL18) strain has been deposited in the China Type Culture Collection Center on March 24, 2022. The deposit address is No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province. The deposit number is CCTCC NO: M 2022306, and the classification name is Bifidobacterium longum. Bifidobacterium lactis HH‑BA68, Lactobacillus rhamnosus PB‑LR76 and Lactobacillus reuteri PB‑LR09 are all existing biological materials that have been published and available to the public. The applicant has published patent documents such as Chinese patent CN 111500483A and Chinese patent Published in CN111991428 A, etc., the previous deposit information is: Bifidobacterium lactis HH‑BA68 is deposited in the China Type Culture Collection Center, and the deposit number is CCTCC NO: M 20211125; the Lactobacillus rhamnosus PB‑LR76 is deposited in China The Type Culture Collection Center, the preservation number is CCTCC NO: M2018887; the Lactobacillus reuteri PB-LR09 is deposited in the China Type Culture Collection Center, the preservation number is CCTCC NO: M2018888.

Preparation of bacterial powder: Bifidobacterium longum HH‑BL18, Bifidobacterium lactis HH‑BA68, Lactobacillus rhamnosus PB‑LR76, and Lactobacillus reuteri PB‑LR09 were inoculated into MRS liquid culture medium, and at the end of carrying out fermentation under appropriate conditions to obtain the corresponding probiotic liquid. Centrifuge the obtained fermentation bacterial liquid and collect the precipitate to obtain bacterial mud of four kinds of probiotics. Add appropriate freeze-drying protective agent to the bacterial mud and then perform vacuum freeze-drying to obtain Bifidobacterium longum HH‑BL18 bacterial powder and milk. Bifidobacterium HH‑BA68 bacteria powder, Lactobacillus rhamnosus PB‑LR76 bacteria powder, and Lactobacillus reuteri PB‑LR09 bacteria powder.

5. Verification of the effect of improving symptoms of respiratory diseases
Establishment of the model group: The experimental guinea pigs (190 adult healthy guinea pigs, half male, and female) were randomly divided into 19 groups, 10 in each group, first-class British breed, weighing 315 ~ 457 g. 10 μL of 10% TDI olive oil solution was dropped into the nose to create a nasal hypersensitivity test model.
Experimental groups: blank control group (healthy guinea pigs, no medication); model control group (experimental model guinea pigs, no medication); negative control group (experimental model guinea pigs are given a freeze-dried protective agent without active ingredients); test group 1-11, control group 1-5; among them, the specific dosage ingredients of test group 1-11 and control group 1-4 are as shown in the table below, in parts by weight (unit: g); control group 5 is commercially available Loratadine.

Note: "X" represents the sum of the bacterial powder fractions of Bifidobacterium longum HH-BL18 and Bifidobacterium lactis HH-BA68; "Y" represents the rhamnosus milk The sum of the bacterial powder fraction of Lactobacillus reuteri PB-LR76 and the bacterial powder fraction of Lactobacillus reuteri PB-LR09; "-" indicates that it has no calculation significance.

Test method: Typical nasal itching, sneezing, and runny nose appeared after 6 days of modeling; then, the blank control group, negative control group, and test group were given the corresponding drug 2 mg/kg by intragastric administration once a day for one week. (7 days). After administration, the guinea pig's nasal symptoms such as nasal itching, runny nose, and sneezing were recorded and their severity was recorded. The observation time is within 30 minutes after administration.

Test results: The test results after administration on the 4th day are shown in the table below.

As can be seen from the table, in the test results after administration on the 4th day: the therapeutic effects of test groups 7‑11 were significantly better than those of commercially available loratadine (control group 5), especially the test group 11 had the best therapeutic effect. All symptoms have disappeared, and the curative effect is rapid; the therapeutic effect of test group 5-6 is second, which is equivalent to control group 5; the symptoms of test group 1-4 have begun to be significantly relieved, and the symptoms of the control group 1-4 have not been seeing significant improvement.
By the end of the seventh day of administration, all symptoms in test groups 7-11 had disappeared, and all symptoms in test groups 5-6 and control group 5 had disappeared; in test groups 1-4, slightly runny nose symptoms still existed and less frequent nose itching, scratching, and sneezing; all symptoms in the control group 1-4 were slightly improved.
In summary, the above strain composition can quickly relieve the symptoms of nasal itching, sneezing, and runny nose, and has a significant therapeutic effect on allergic rhinitis drugs.

Hot Tags: allergic rhinitis probiotics capsules, manufacturers, factory, custom, wholesale, bulk, probioticos lactobacillus plantarum, lactobacillus acidophilus for men, dried lactobacillus acidophilus, lactobacillus johnsonii buy, acidophilus probiotico, probiotika rhamnosus